Quantcast
Last updated on April 16, 2014 at 5:49 EDT

Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors

June 30, 2009

NEW HAVEN, Conn., June 30 /PRNewswire/ — Rib-X Pharmaceuticals, Inc., a development stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic resistant infections, announced today that Russell Greig, Ph.D., of SR One venture capital, has been appointed to the Company’s Board of Directors. Rib-X’s board now consists of eleven members.

“We are extremely pleased that Russell Greig has joined the Rib-X Board of Directors,” said Dr. Susan Froshauer, President and Chief Executive Officer, Rib-X. “Russell brings an impressive mix of both R&D and business development experience that will be crucial as the Company grows and continues to move products through the development pipeline.”

Russell Greig is President of SR One, the venture capital arm of GlaxoSmithKline (GSK). Prior to joining SR One, he served as President of GSK’s Pharmaceuticals International from 2003 to 2008, and also served on the GSK Corporate Executive Team. Dr. Greig originally joined GSK (then SmithKline & French) in 1980 in the Departments of Tumor and Cell Biology. In 1991, following the merger with Beecham, he was appointed Vice President, Project Management. From 1993 to 1996, he served as Vice President and Director of Advanced Technologies in Genetics with special responsibility for managing collaborations with The Institute of Genomic Research and Human Genome Sciences. In 1996 Dr. Greig joined SmithKline Beecham’s European Pharmaceutical Operations as Vice President and Director of European Market Development, and was later appointed Managing Director and General Manager of SmithKline Beecham’s UK Pharmaceuticals. Following the merger of SmithKline Beecham with Glaxo Wellcome in 2000, he returned to the United States as Senior Vice President for Worldwide Business Development.

Dr. Greig also serves on the boards of Genocea Biosciences and the Edinburgh BioQuarter Commercialisation Advisory Group, and is a member of the Imperial College Innovations Healthcare Advisory Board and a board observer for Anaphore, Inc. He holds a Ph.D. in Biochemistry from the University of Manchester, England and is a former Fulbright Scholar.

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. NDAs for Rib-X’s most advanced compounds, delafloxacin and radezolid, are anticipated in the 2011/2012 timeframe. The Company’s underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company’s integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X’s iterative intelligent engine has yielded several distinctive new antibiotics that can be used for the treatment of either community- or hospital-acquired infections. The Company has recently completed Phase 2 trials in complicated skin and skin structure infections with the IV form of delafloxacin (RX-3341), and is currently in Phase 2 trials with radezolid (RX-1741), an oxazolidinone that was discovered at Rib-X, as an oral/IV agent for treatment of serious Gram-positive infections and community or hospital acquired pneumonias. The Rx-04 discovery program is developing novel classes of antibiotics active against multi-drug resistant Gram-negative bacteria and the Rx-02 discovery program is focused on developing an IV/oral macrolide active against methicillin-resistant S. aureus, multidrug-resistant Streptococcus pneumoniae and S. pyogenes.

For more information on the Rib-X mission and the pipeline, please visit the Company website at www.rib-x.com.

For further information please contact:

    Media:
    Irma Gomez-Dib
    FD Life Sciences
    Tel: 212-850-5761
    irma.gomez-dib@fd.com

    Investors:
    John Capodanno
    FD Life Sciences
    Tel: 212-850-5705
    John.capodanno@fd.com

SOURCE Rib-X Pharmaceuticals, Inc.


Source: newswire